UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities

UPLIZNA Market Poised for Growth Through 2034 as Expanding Indications and Rising Demand Drive Sales Opportunities Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "UPLIZNA Sales Forecast and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.

The UPLIZNA sales forecast and market analysis report provides a comprehensive assessment of the therapy's commercial outlook across approved and potential autoimmune indications in the seven major markets (7MM): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. Covering the period from 2020 to 2034, the report examines historical sales, current market performance, future revenue potential, regulatory milestones, pricing, reimbursement, competitive positioning, and clinical development.

Key Factors Driving UPLIZNA Market Growth

Recent UPLIZNA Developments

In February 2026, Amgen announced that the European Commission approved UPLIZNA as an add-on to standard therapy for adults with generalized myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive. The approval introduced an additional targeted treatment option with twice-yearly maintenance dosing following the initial loading regimen.

UPLIZNA Drug Overview

UPLIZNA, or inebilizumab, was developed by Horizon Therapeutics, which Amgen acquired in 2023. The therapy received its initial U.S. Food and Drug Administration approval in 2020 for anti-AQP4 antibody-positive NMOSD in adults. Subsequent regulatory expansion into other antibody-mediated autoimmune diseases has strengthened its commercial potential.

UPLIZNA induces antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and phagocytosis, resulting in depletion of CD19-positive B cells. Its clinical and commercial profile must be evaluated alongside applicable safety information, including warnings and precautions related to infusion reactions, infections, hepatitis B virus reactivation, hypogammaglobulinemia, and progressive multifocal leukoencephalopathy.

Scope of the UPLIZNA Market Report

Market, Clinical, and Competitive Assessment

The UPLIZNA market forecast evaluates revenue potential by indication and geography, including projected market size, peak sales potential, pricing strategies, and reimbursement conditions. The analysis considers prescription growth, specialist adoption, eligible patient populations, treatment duration, regulatory expansion, and competition from established and emerging therapies.

The clinical assessment covers trials in approved and potential indications, including study interventions, conditions, development status, and anticipated completion timelines. The competitive landscape evaluates UPLIZNA's market positioning, clinical differentiation, dosing profile, efficacy, safety considerations, and relative strengths and weaknesses.

The report also reviews regulatory approvals, expected launch timelines, commercial partnerships, licensing agreements, acquisitions, and other strategic activities that may influence UPLIZNA sales. Competitive pipeline analysis identifies therapies that could affect market share in NMOSD, IgG4-related disease, generalized myasthenia gravis, systemic sclerosis, and systemic lupus erythematosus.

UPLIZNA Market Outlook

UPLIZNA's market outlook is supported by strong commercial growth, Amgen's global reach, a differentiated CD19-targeted profile, and expansion across multiple autoimmune indications. Broader prescribing and regulatory approvals may increase the eligible patient population through 2034. However, competition from marketed products and late-stage therapies, regional reimbursement requirements, safety monitoring, and pricing pressure may influence future uptake.

Key Questions Addressed

Research Methodology

The UPLIZNA market analysis is based on internal databases, primary research, secondary research, and in-house assessment by industry experts. Sources include regulatory authority publications, company disclosures, clinical trial registries, peer-reviewed journals, trade publications, industry associations, market databases, white papers, and other publicly available materials. The combined analysis provides a structured view of UPLIZNA's historical performance, current market position, and sales potential through 2034.

Key Topics Covered:

1. Report Introduction

2. UPLIZNA Overview in approved indications like Immunoglobulin G4-related disease, Neuromyelitis optica, and Myasthenia gravis; as well as potential indication like Systemic scleroderma and Systemic lupus erythematosus

2.1. Product Detail

2.2. UPLIZNA Clinical Development

2.2.1. UPLIZNA Clinical studies

2.2.2. UPLIZNA Clinical trials information

2.2.3. Safety and efficacy

2.3. Other Developmental Activities

2.4. Product Profile

3. UPLIZNA Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging UPLIZNA Therapies)

5. UPLIZNA Market Assessment

5.1. UPLIZNA Market Outlook in approved and potential indications

5.2. 7MM Analysis

5.2.1. UPLIZNA Market Size in the 7MM for approved and potential indications

5.3. Country-wise Market Analysis

5.3.1. UPLIZNA Market Size in the United States for approved and potential indications

5.3.2. UPLIZNA Market Size in Germany for approved and potential indications

5.3.3. UPLIZNA Market Size in France for approved and potential indications

5.3.4. UPLIZNA Market Size in Italy for approved and potential indications

5.3.5. UPLIZNA Market Size in Spain for approved and potential indications

5.3.6. UPLIZNA Market Size in the United Kingdom for approved and potential indications

5.3.7. UPLIZNA Market Size in Japan for approved and potential indications

6. UPLIZNA SWOT Analysis

7. Analysts' Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. Publisher Capabilities

10. Disclaimer

11. About the Publisher

12. Report Purchase Options

List of Tables

Table 1: UPLIZNA, Clinical Trial Description, 2023

Table 2: UPLIZNA, General Description

Table 3: Competitive Landscape (Marketed Therapies)

Table 4: Competitive Landscape (Emerging Therapies)

Table 5: UPLIZNA's pricing and cost Assumptions

Table 6: UPLIZNA's Sales Analysis in the 7MM, in USD million (2020-2034)

Table 7: UPLIZNA Market Size in the US, in USD million (2020-2034)

Table 8: UPLIZNA Market Size in Germany, in USD million (2020-2034)

Table 9: UPLIZNA Market Size in France, in USD million (2020-2034)

Table 10: UPLIZNA Market Size in Italy, in USD million (2020-2034)

Table 11: UPLIZNA Market Size in Spain, in USD million (2020-2034)

Table 12: UPLIZNA Market Size in the UK, in USD million (2020-2034)

Table 13: UPLIZNA Market Size in Japan, in USD million (2020-2034)

List of Figures

Figure 1: UPLIZNA's Sales Analysis in the 7MM, USD million (2020-2034)

Figure 2: UPLIZNA Market Size in the United States, USD million (2020-2034)

Figure 3: UPLIZNA Market Size in Germany, USD million (2020-2034)

Figure 4: UPLIZNA Market Size in France, USD million (2020-2034)

Figure 5: UPLIZNA Market Size in Italy, USD million (2020-2034)

Figure 6: UPLIZNA Market Size in Spain, USD million (2020-2034)

Figure 7: UPLIZNA Market Size in the United Kingdom, USD million (2020-2034)

Figure 8: UPLIZNA Market Size in Japan, USD million (2020-2034)

For more information about this report visit https://www.researchandmarkets.com/r/42yebq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.